Deprodone is a steroid that was approved in Japan for the treatment of inflammatory skin disorders. The drug is marketed under the name Eclar and contains 0.3% of the prodrug, deprodone propionate.

Bunaprolast has been described as the most potent antioxidant inhibitor of endothelial activation of NF-kB and gene expression of E-selectin and vascular cell adhesion molecule-1. Bunaprolast is a potent inhibitor of leukotriene B4 production in human whole blood and undergoes deacetylation to an initial metabolite with similar pharmacological potency. The in vivo demonstration of inhibition of pulmonary bronchoconstriction by this compound, in a model known to be leukotriene sensitive, coupled with its potent in vitro inhibition of 5-lipoxygenase enzymes, suggests bunaprolast may be of use in 5-lypoxygenase-mediated models of asthma.

Efloxate is a coronary vasodilator developed in 1959 in Italy by Recordati and used for the treatment of angina pectoris. The drug is no longer marketed.

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) analog of Diclofenac. It is used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The dose is 100 mg twice daily, and should not be given to people with porphyria or breastfeeding mothers and is not recommended for children. Aceclofenac is a cytokine inhibitor. Aceclofenac works by blocking the action of a substance in the body called cyclo-oxygenase. Cyclo-oxygenase is involved in the production of prostaglandins (chemicals in the body which cause pain, swelling and inflammation). Aceclofenac is the glycolic acid ester of diclofenac. The incidence of gastric ulcerogenicity of aceclofenac has been reported to be significantly lower than that of other frequently prescribed NSAIDs: for instance, 2-fold less than naproxen, 4-fold less than diclofenac, and 7-fold less than indomethacin. Aceclofenac is metabolized in human hepatocytes and human microsomes to form [2-(2',6'-dichloro-4'-hydroxy- phenylamino)phenyl] acetoxyacetic acid as the major metabolite, which is then further conjugated.

Nomegestrol acetate (NOMAC) is a 19-norprogesterone derivative with high biological activity at the progesterone receptor, a weak anti-androgenic effect, but with no binding to estrogen, glucocorticoid or mineralocorticoid receptors. Nomegestrol has been developed by the Monaco-based company Théramex SAM (a Teva subsidiary). Nomegestrol acetate has been used successfully for the treatment of some gynaecological disorders (menstrual disturbances, dysmenorrhoea, premenstrual syndrome) and as a component of hormone replacement therapy in combination with estradiol for the relief of menopausal symptoms; it has been approved in Europe as monotherapy for the treatment of the menopausal syndrome, uterine diseases and menorrhagia, and in combination with an estrogen for the treatment of menopausal symptoms. Nomegestrol acetate in combination with estradiol is used as an oral contraceptive.

Adafenoxate exerts nootropic and anxiolytic properties in rodents. Adafenoxate inhibits monoamine oxidase and cAMP phosphodiesterase activity. Adafenoxate inhibits monoamine uptake and regulates the density of the 5-HT1 sites in the brain.

Guacetisal (Broncaspin) is a bronchomucotropic synthesized by the Bayer Italia S.p.A. Research Laboratories. It is obtained from the esterification of acetylsalicylic acid with guaiacol. Guacetisal was used for the treatment of chronic bronchitis and other inflammatory diseases of the respiratory tract. Guacetisal, used rectally, proved to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.

FORMOCORTAL is a corticosteroid used in ophthalmology and in dermatology.

Prednimustine is chlorambucil ester of prednisolone. Prednimustine is a cytostatic agent. Prednimustine is active against a wide variety of experimental tumors both in vivo and in vitro. In many of these tumor systems, prednimustine exhibits distinct advantages over a mixture of its constituents, chlorambucil and prednisolone. In vitro, a higher cell kill is obtained, and in vivo, at doses that are equally effective, prednimustine is less toxic. It has been used in the treatment of various malignancies, including chronic lymphatic leukaemia and non-Hodgkin's lymphomas. It has also been tested for use in the treatment of breast cancer

The phenylpyrazosteroid cortivazol is a selective agonist ligand for the glucocorticoid receptor (GR), a steroid receptor member of the nuclear receptor superfamily of transcription factors. Cortivazol is an apoptotic, anti-inflammatory and immunosuppressive agent that has been used in the treatment of diskogenic radiculopathy, back pain, osteoarthritis and acute childhood lymphoblastic leukemia. Cortivazol has potent antileukemic activity in childhood ALL. Its activity is related to cell cycle arrest and induction of apoptosis. Cortivazol (Altim) is indicated in rheumatological diseases: - In intra-articular injection: inflammatory arthritis, advanced osteoarthritis. - In periarticular injection: tendinitis, bursitis. - In injection of soft tissue: talalgia, carpal tunnel syndrome, Dupuytren’s contracture. - In epidural injection: radiculalgia